Hello, and welcome back to The Kable. Last week, we had a fairly light Kable. This week, it is even lighter. In fact, it it so light this week we almost didn't publish it. But hey, these bills don't pay themselves, do they?
First, some excellent news from the US FDA, of all places. The agency approved a drug that could just be the first step towards endi…